Format

Send to

Choose Destination
Clin Infect Dis. 2006 Nov 1;43(9):e89-91. Epub 2006 Sep 27.

No effect of pyridoxine on the incidence of myelosuppression during prolonged linezolid treatment.

Author information

1
Fourth Department of Internal Medicine, Attiko University General Hospital, Haidari, Greece. dplach@med.uoa.gr

Abstract

Complications of long-term linezolid administration include anemia and thrombocytopenia. A recent report has suggested that pyridoxine may prevent myelosuppression. Pyridoxine was administered to 24 patients with bone infections who were being treated with linezolid. Thrombocytopenia occurred in 11 patients (45.8%), and anemia occurred in 6 (25%). We concluded that treatment wtih pyridoxine is unlikely to benefit patients who have been receiving linezolid for >2 weeks.

PMID:
17029128
DOI:
10.1086/508280
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Silverchair Information Systems
Loading ...
Support Center